GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute

LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

When Ebola virus disease swept through Guinea, Liberia and Sierra Leone in 2014, the world saw firsthand the shortcomings of the global response.

Global Communities had spent four years building access to safe sanitation in Liberia when the Ebola epidemic struck and revealed a surprising impact.

As experimental Ebola vaccines start to head toward large clinical trials in Africa, a report released by Wellcome Trust and the Center for Infectious